Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 298 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo inhaler Clear all

Conditions: Exercise-induced Bronchospasm
Interventions: albuterol aerosol by HFA MDI, albuterol aerosol by HFA BOI, placebo aerosol by HFA; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 3
States / cities: Denver, Colorado • Englewood, Colorado • Lakewood, Colorado

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: placebo to tiotropium + olodaterol, tiotropium +olodaterol, tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: San Diego, California • Torrance, California • Hartford, Connecticut

Conditions: Asthma
Interventions: GW642444, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Cypress, California • Huntington Beach, California • Denver, Colorado + 2 more

Conditions: Type 1 Diabetes
Interventions: Formoterol, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pulmonary Disease, Chronic Obstructive, Asthma
Interventions: BI 1744CL; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 22
States / cities: Birmingham, Alabama • Lakewood, California • Denver, Colorado + 17 more

Conditions: Eosinophilic Esophagitis
Interventions: Retrospective evaluation of endoscopy prior to study drug, Symptom Survey, Medication Compliance Phone Call, Endoscopy while on study drug, Fluticasone, Omeprazole, Placebo oral capsule; Diagnostic Test · Other · Drug
Lead sponsor: Claire Daniels; Federal
Eligibility: 6 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: Lorazepam 1 mg IM, Inhaled loxapine 10 mg, Inhaled Placebo, Placebo IM; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 50 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions: Placebo, Seralutinib, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Fresno, California • Albuquerque, New Mexico • Richmond, Virginia

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Arformoterol, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 73
States / cities: Birmingham, Alabama • Brimingham, Alabama • Jasper, Alabama + 61 more

Conditions: Exercise-induced Arterial Hypoxemia
Interventions: Cetirizine HCl, Placebo; Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Secondhand Smoke, Air Trapping, Tobacco, Airflow Limitation, Hyperinflation, Obstructive Lung Disease
Interventions: Albuterol, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 80 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Asthma
Interventions: Beclomethasone dipropionate, Placebo, Albuterol/salbutamol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 1,113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 94
States / cities: Costa Mesa, California • Huntington Beach, California • Long Beach, California + 77 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: NVA237 12.5 µg once daily, NVA237 25.0 µg once daily, NVA237 12.5 µg twice daily, NVA237 50.0 µg once daily, NVA237 25.0 µg twice daily, NVA237 100.0 µg once daily, NVA237 50.0 µg twice daily, Placebo to NVA237 once daily; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Anniston, Alabama • San Diego, California • Torrance, California + 3 more

Conditions: Asthma in Children, Humans, Hispanic Americans, Child
Interventions: SmartInhaler with reminder function turned on, SmartInhaler; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 5 Years to 17 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Asthma
Interventions: Omalizumab, Placebo, Fluticasone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 56
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more

Conditions: Cystic Fibrosis
Interventions: BI 1265162, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Orlando, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 5 more

Conditions: Asthma
Interventions: ELLIPTA inhaler, Placebo Inhalation Aerosol (MDI); Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 15
States / cities: Huntington Beach, California • Newport Beach, California • Vista, California + 12 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Glycopyrronium bromide, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 33
States / cities: Birmingham, Alabama • Fairhope, Alabama • Glendale, Arizona + 30 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 14
States / cities: Birmingham, Alabama • Downey, California • Los Angeles, California + 11 more

Conditions: Asthma
Interventions: Placebo, BI 54903, Fluticasone propionate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 41
States / cities: Fountain Valley, California • Fullerton, California • Huntington Beach, California + 38 more

Conditions: Asthma
Interventions: Antipyrine-benzocaine otic solution, Glycerin with Oxyquinoline Sulfate; Drug · Other
Lead sponsor: Global United Pharmaceutical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Healthy Volunteers
Interventions: (Part A) MKND-201, Placebo, (Part B) MKND-201; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Batefenterol + Fluticasone Furoate, Placebo, Albuterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more

Conditions: Asthma
Interventions: FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg, Placebo; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 19
States / cities: Phoenix, Arizona • Anaheim, California • Long Beach, California + 16 more

Search by objective public record fields.

Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects

Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone

ADASUVE-Lorazepam Drug-Drug Interaction

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers

Secondhand Smoke Respiratory Health Study

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Interventions To Help Asthma Clinical Adherence

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma

A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands